The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Benefits of measuring urinary protein/creatinine ratio in lenvatinib treatment for unresectable hepatocellular carcinoma.
 
Koki Morishita
No Relationships to Disclose
 
Hidetaka Suzuki
No Relationships to Disclose
 
Junko Tauchi
No Relationships to Disclose
 
Misaki K Takeno
No Relationships to Disclose
 
Shota Yamaguchi
No Relationships to Disclose
 
Kanae Inoue
No Relationships to Disclose
 
Tomonao Taira
No Relationships to Disclose
 
Hiroki Eguchi
No Relationships to Disclose
 
Kei Okumura
No Relationships to Disclose
 
Taro Shibuki
No Relationships to Disclose
 
Tomoyuki Satake
No Relationships to Disclose
 
Kazuo Watanabe
No Relationships to Disclose
 
Hiroshi Imaoka
Honoraria - AstraZeneca; Kaneka Medix; Nihon Servier; Yakult Honsha
Consulting or Advisory Role - Nihon Servier
Research Funding - Ono Pharmaceutical
 
Mitsuhito Sasaki
No Relationships to Disclose
 
Shuichi Mitsunaga
Honoraria - Eisai; Pfizer; Toray Industries
Speakers' Bureau - Ono Pharmaceutical
Research Funding - Ajinomoto; Astellas Pharma; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Toray Industries
Patents, Royalties, Other Intellectual Property - Ajinomoto
 
Toshikatsu Kawasaki
Consulting or Advisory Role - Nippon Kayaku
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)